RecruitingPhase 4NCT03898154

Perioperative Glucocorticoid Administration in the Treatment of Adult Distal Radius Fractures

The Effect on Wrist Range of Motion With Perioperative Glucocorticoid Administration in the Treatment of Adult Distal Radius Fractures: A Randomized Controlled Trial


Sponsor

C. Liam Dwyer

Enrollment

200 participants

Start Date

Jul 10, 2019

Study Type

INTERVENTIONAL

Conditions

Summary

The purpose of this investigation is to compare functional outcome measures and range of motion for patients receiving glucocorticoid (GC) injections versus those not receiving GCs for the treatment of distal radius fractures. The investigators hypothesize that patients who receive GC will have improved ROM and functional outcome measures compared to patients who do not receive GC. In addition, this study aims to determine if there is a difference in rates of complications and postoperative pain control between the GC and non-GC groups. In order to accomplish these aims, the investigators will conduct a prospective, randomized, controlled investigation.


Eligibility

Min Age: 18 Years

Inclusion Criteria2

  • Patient 18 years of age and older.
  • Patients undergoing ORIF with VP fixation of an acute, isolated DRF with or without associated distal ulna fracture and with or without associated carpal tunnel release

Exclusion Criteria10

  • Worker's compensation patient
  • Non-operatively treated fractures
  • Open fractures
  • Preoperative neurovascular injury
  • Coexisting fractures or injuries
  • Diabetes mellitus
  • Allergy or contraindication to GCs
  • Associated non-orthopedic injury that would prohibit the administration of GCs
  • Patients currently incarcerated
  • Pregnant patients

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGDexamethasone

Intraoperative: Single intraoperative dose of 10 mg intravenous dexamethasone

DRUGMethylprednisolone

Postoperative: A 6-day oral methylprednisolone (oral GC) taper course. The oral GC taper course begins on the day of surgery and includes 24mg on day 1, 20mg on day 2, 16mg on day 3, 12mg on day 4, 8mg on day 5, and 4mg on day 6


Locations(1)

Geisinger Woodbine

Danville, Pennsylvania, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT03898154


Related Trials